Diagnostic efficacy of hemorheological measurement system(rheoscan)

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-788
Sohee Kim, Chanhee Kyung*, Min Kyung Kim, Jiyoon Ha, Haeri Baek, Eunjin Kwon, Tae Woong Noh, Shinae Kang, Kyung Rae Kim, Jong Suk Park and Chul Woo Ahn
Gangnam Severance Hospital, Seoul, South Korea
Several hemorheological parameters, such as erythrocyte deformability, erythrocyte aggregation are altered in patients with diabetes mellitus. These changes of erythrocyte in turn make whole blood more viscous and may play an important role on the pathogenesis of vascular complications of diabetes mellitus. So we intended to examine erythrocyte deformability and aggregation in patients with type 2 diabetes, and assess the differences of these parameters compared with healthy controls.

81 subjects were enrolled. The erythrocyte deformability was measured in terms of elongation index (EI) with microfluidic ektacytometer, RheoScan. The aggregation index (AI) was measured with RheoScan, too. All subjects were divided by 5 groups as follows: Healthy control (n=12), prediabetes (pre-DM, n=7), diabetes without vascular complications (DM-no Cx, n=24), diabetes with microvascular complications (DM-microCx, n=28) and diabetes with macrovascular complications (DM-macroCx, n=10).

 A significant reduction of erythrocyte deformability was observed in DM-microCx group and DM-macroCx compared with healthy control (0.325 & 0.325 vs. 0.344, p<0.05). Also, EI was significantly decreased in the group of higher HbA1c level (a1c≥9%) compared with in the group of lower HbA1c level (a1c<7%, 0.328 vs. 0.339, p<0.05).

EI is a sensitive parameter to detect impairment of erythrocyte in diabetic process. The results in this study suggest that significant reduction in the EI may have correlation with diabetic vascular complications, and furthermore could be one of the indicators of these complications.

Nothing to Disclose: SK, CK, MKK, JH, HB, EK, TWN, SK, KRK, JSP, CWA

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm